Table 2.
Immunostaining for TauΔCsp6, PHF-1, or Aβ in NCI, MCI, and AD Cases
| Individual | Age at death (years) | Education (years) | Gender | MMSE score | Days since last MMSE at death | Clinical diagnosis | Braak stage score | NFT
|
NPT
|
NP
|
Global cognitive score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TauΔ-Csp6 | PHF-1 | TauΔ-Csp6 | PHF-1 | Aβ | TauΔ-Csp6 | PHF-1 | |||||||||
| MMSE 0 to 5 AD | |||||||||||||||
| 1 | 89 | 18 | M | 2 | 61 | 4 | V | 3 | 3 | 3 | 3 | 1 | 3 | 1 | −3.66753 |
| 2 | 90 | 11 | F | 0 | 323 | 4 | V | 3 | 3 | 3 | 3 | 1 | 3 | 3 | −3.44916 |
| 3 | 84 | 16 | M | 3 | 29 | 4 | V | 3 | 3 | 3 | 3 | 1 | 3 | 1 | −3.86259 |
| 4 | 90 | 22 | M | 1 | 349 | 4 | IV | 3 | 3 | 3 | 3 | 1 | 3 | 1 to 2 | −4.24437 |
| MMSE 6 to 10 AD | |||||||||||||||
| 1 | 90 | 20 | F | 10 | 331 | 4 | V | 3 | 3 | 3 | 3 | 2 | 3 | 1 | −2.53453 |
| 2 | 95 | 16 | F | 7 | 323 | 4 | V | 3 | 1 | 3 | 1 | 1 | 3 | .5 | −2.38578 |
| 3 | 97 | 16 | F | 9 | 339 | 4 | V | 3 | 3 | 3 | 3 | 1 to 2 | 3 | 3 | −1.49416 |
| 4 | 94 | 16 | F | 7 | 243 | 4 | V | 3 | 4 | 3 | 4 | 4 | 3 | 4 | −2.69227 |
| MMSE 11 to 15 AD | |||||||||||||||
| 1 | 92 | 19 | M | 15 | 202 | 4 | V | 3 | 3 | 3 | 3 | 2 | 3 | 2 | * |
| 2 | 86 | 20 | M | 12 | 145 | 4 | V | 3 | 3 | 3 | 3 | 1 to 2 | 3 | 3 | −2.53204 |
| 3 | 94 | 22 | M | 15 | 265 | 4 | IV | 2 | 3 | 1 to 2 | 3 | 1 | 2 | 1 | −2.95918 |
| MMSE 16 to 20 AD | |||||||||||||||
| 1 | 83 | 16 | F | 16 | 86 | 4 | V | 3 | 3 | 3 | 3 | 1 | 3 | 1 | −1.83198 |
| 2 | 88 | 24 | F | 19 | 211 | 4 | IV | 3 | 3 | 1 to 2 | 3 | 2 | 2 | 1 | −1.19181 |
| 3 | 87 | 8 | M | 20 | 350 | 4 | I | 1 | .5 | 0 to 1 | 0 | 1 | 0 to 1 | 0 | −1.44703 |
| MMSE 21 to 25 AD | |||||||||||||||
| 1 | 84 | 16 | F | 22 | 190 | 4 | V | 3 | 3 | 3 | 3 | 2 | 3 | 3 | −1.53034 |
| 2 | 84 | 22 | F | 24 | 276 | 4 | IV | 3 | 3 | 3 | 3 | 2 | 3 | 2 | −0.97412 |
| 3 | 86 | 20 | M | 21 | 381 | 4 | IV | 3 | 2 to 3 | 3 | 2 to 3 | 1 | 2 | 2 to 3 | −1.26995 |
| 4 | 87 | 18 | M | 24 | 333 | 4 | V | 3 | 3 | 3 | 3 | 1 | 3 | 1 | −1.23048 |
| MMSE 26 to 30 MCI | |||||||||||||||
| 1 | 90 | 20 | F | 26 | 350 | 2 | III | 3 | 3 | 3 | 3 | 0 | 1 to 2 | 1 | −0.8602 |
| 2 | 92 | 19 | F | 29 | 98 | 2 | IV | 3 | 3 | 2 | 3 | 3 | 3 | 3 | −0.43836 |
| 3 | 95 | 25 | F | 28 | 1442 | 2 | II | 2 | 3 | 3 | 3 | 2 | 2 | 1 | −0.39552 |
| 4 | 82 | 18 | M | 29 | 282 | 2 | III | 2 | 3 | 2 | 3 | 0 to 1 | 0 | 1 | −0.45539 |
| 5 | 76 | 16 | M | 26 | 318 | 2 | II | 0 to 1 | 0 | 0 | 0 | 0 | 0 | 0 | −0.62942 |
| 6 | 88 | 21 | M | 25 | 291 | 2 | I | 0 to 1 | 1 | 0 to 1 | 1 | 0 | 0 | 0 | −0.21812 |
| MMSE 26 to 30 NCI | |||||||||||||||
| 1 | 77 | 18 | F | 29 | 186 | 1 | III | 2 to 3 | 1 | 2 to 3 | 1 | 1 | 1 | 0 | −0.07983 |
| 2 | 78 | 18 | F | 29 | 584 | 1 | II | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0.61261 |
| 3 | 89 | 21 | F | 30 | 289 | 1 | III | 1 | 1 to 2 | 1 | 1 to 2 | 0 | 0 | 0 | 0.5143 |
| 4 | 83 | 16 | M | 28 | 59 | 1 | III | 2 to 3 | 1 | 3 | 1 | 0 | 1 | 0 | −0.61081 |
| 5 | 76 | 25 | M | 28 | 68 | 1 | III | 1 to 2 | 1 to 2 | 2 | 1 to 2 | 0.5 | 1 | 0 | 0.26269 |
| 6 | 74 | 19 | M | 27 | 247 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0.59916 |
A clinical diagnosis of 1 represents NCI, of 2 represents MCI, and of 4 represents AD. AD cases are divided based on MMSE scores as a measure of the severity of the disease. The global cognitive score was assessed as described.17 M, male; F, female.
*
The global cognitive score of this case was not taken at the time that the MMSE score was 15. Scores taken 3 to 7 years before death indicate declining function.